As first-line pharmacologic therapy for the acute treatment of migraine, triptans (i.e. serotonin 5-HT1B/1D agonists) are associated with a risk for cardiovascular/cerebrovascular side effects [37–39]. The gene discussed is HTR1B; the disease is migraine disorder.